Novartis AG (NVS) Earnings Date & Reports

Key Takeaways

• Novartis AG (NVS) is scheduled to report third-quarter 2026 results on Tuesday, October 27, 2026, before the market opens.
• Consensus estimates point to earnings per share (EPS) of roughly $2.24 and revenue of approximately $14.6 billion, near flat versus the prior-year quarter.
• Investors will focus on the company's key growth drivers, including Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix.
• Entresto's loss of exclusivity (the end of patent protection) remains a headwind, weighing on year-over-year comparisons.
• The company has reaffirmed full-year guidance for low single-digit sales growth and a low single-digit decline in core operating income.
• A pending regulatory decision on Pluvicto and the trajectory of core operating margins are among the top items to watch.

Earnings Context and Why It Matters

Novartis is navigating a transitional period as it pivots toward its fast-growing portfolio of innovative medicines. The loss of exclusivity on the blockbuster heart drug Entresto has pressured headline growth, making the performance of newer therapies the central question for investors. In the second quarter of 2026, these growth drivers surged 36% in constant currencies, helping the company return to growth after a weak first half. The third-quarter report will test whether that momentum is sustainable and whether management's confidence in a stronger second half is justified. For a pharmaceutical giant with a broad pipeline and an active acquisition strategy, this update offers an important read on the durability of revenue, margins, and free cash flow.

Earnings Expectations

Analysts expect Novartis to deliver earnings per share near $2.24, according to consensus estimates, with revenue projected around $14.6 billion for the third quarter. That compares with roughly $14.36 billion in revenue in the same period a year earlier, implying only modest growth as the Entresto patent headwind continues to weigh on comparisons.

BofA analysts anticipate third-quarter sales of about $14.3 billion, up approximately 3% year over year, and adjusted EPS of about $2.24, essentially flat from the prior-year quarter. The bank notes that some sales were pulled forward into the second quarter due to a system implementation, and it expects the quarter to land roughly in line with consensus. For context, Novartis exceeded expectations in Q2 2026 with EPS of $2.41 versus a $2.17 estimate, while Q1 2026 EPS of $1.99 came in below the $2.10 consensus.

Key metrics to watch include growth-driver sales, core operating margin, and free cash flow, along with any updates to full-year 2026 guidance.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. As earnings season unfolds, tools like this can help investors quickly surface relevant candidates and monitor changing market conditions. Explore the AI Screener to streamline your research process.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter report is cautiously constructive. Shares reacted positively to the strong Q2 results in July, when EPS and revenue both beat expectations and growth drivers demonstrated accelerating momentum. Since then, attention has shifted to whether the company can sustain that trajectory through the back half of the year.

Key risk factors include the ongoing drag from Entresto's loss of exclusivity, the timing of the Pluvicto regulatory decision, and margin pressure from acquisition-related costs and product mix. A slightly elevated core operating margin outlook from BofA, versus consensus, suggests some investors see room for the company to outperform. The market will likely reward confirmation of accelerating growth-driver sales, while any sign of margin erosion or a cautious guidance update could temper enthusiasm.

Forward Outlook and Key Factors to Monitor

Looking ahead, the third-quarter update will help clarify whether Novartis can meet its full-year targets of low single-digit sales growth and a low single-digit decline in core operating income. Management has signaled it expects a stronger second half, so investors will be listening closely for any change to that stance.

A central catalyst is the pending decision on Pluvicto, a targeted cancer therapy. New indications could help reaccelerate sequential growth in the United States, where uptake has been a point of focus. Beyond Pluvicto, watch the sustained performance of Kisqali and Kesimpta in oncology and multiple sclerosis, as well as Leqvio and Scemblix, which have emerged as notable contributors.

Margin trends also deserve attention. The second quarter's core operating margin slipped to 41.2%, partly reflecting costs tied to the Avidity acquisition and an unfavorable product mix. Investors should monitor whether research and development spending and acquisition integration costs continue to pressure profitability, or whether operating leverage begins to improve.

Finally, the company's disciplined approach to mergers and acquisitions (M&A, the buying or combining of companies) and its pipeline readouts remain important. Novartis has signaled it will stay selective on dealmaking while awaiting key clinical and regulatory milestones, making these forward indicators central to the long-term growth story.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations